Holen Sie sich die Stockscreener-App
0.00
100.00%
-8.28
Schlusskurs vom Vortag:
$8.28
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$413.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
0.00
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Jefferies | Buy |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Top Cybin (HELP) Competitors 2026 - MarketBeat
Aug PreEarnings: Will Cybin Inc stock recover after earningsDay Trade & Expert Curated Trade Ideas - baoquankhu1.vn
Market Rankings: Can Cybin Inc be the next market leaderWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
symbol__ Stock Quote Price and Forecast - CNN
Aug Update: Can Cybin Inc deliver consistent EPS growthMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cybin (NASDAQ:HELP) Shares Down 2.1%Time to Sell? - MarketBeat
Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th - Psychedelic Alpha
Bank Watch: Can Cybin Inc be the next market leaderWeekly Trade Review & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Ideas: Can Cybin Inc be the next market leader2026 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Cybin Inc.: Fundamental Analysis and Financial Ratings | R7E | CA23256X4075 - marketscreener.com
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Cybin (HELP) Institutional Ownership 2026 $HELP - MarketBeat
Why Is Cybin Inc. (CYBN.NE) Stock Down Today? - Meyka
Investor Mood: What hedge funds are buying Cybin IncQuarterly Investment Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Aug EndMonth: What hedge funds are buying Cybin IncShort Setup & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data - Yahoo Finance
Published on: 2026-03-08 02:13:31 - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP) - The Globe and Mail
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Aug Shorts: Does Cybin Inc stock have upside surprise potential2025 Market Trends & Weekly Top Gainers Alerts - baoquankhu1.vn
Clinical Progress Fails to Lift Cybin's Stock as Regulatory Revisions Weigh - AD HOC NEWS
Analysis Recap: Is Cybin Inc impacted by rising ratesJuly 2025 Gainers & AI Powered Market Entry Strategies - baoquankhu1.vn
Cybin Inc. (CYBN.NE NEO) down 30.12% on 06 Mar 2026: key support ahead - Meyka
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - finance.yahoo.com
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Sahm
Jefferies Maintains Buy on HELP (Cybin Inc. Common Stock) Mar 2026 - Meyka
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety DisorderSlideshow - Seeking Alpha
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Investing News Network
FY2026 Earnings Forecast for Cybin Issued By HC Wainwright - MarketBeat
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
0.51%
Kapitalisierung:
|
Volumen (24h):